5 things to know on Anthem stock after Zacks Investment downgrades to sell

Growing uncertainty over the Cigna-Anthem deal coupled with weak exchange business and low interest rates caused Zacks Investment Research to downgrade Anthem to a sell rating. Here's what you should know, Nasdaq reports.

1. One of the most prominent reasons behind the downgrade is the Cigna/Anthem merger. The companies are in the midst of a long and expensive legal battle with the Department of Justice over said merger that could end with Anthem paying Cigna $1.85 billion if merger fails.

2. Zacks coupled that with the losses on the public exchange Anthem has had to other insurers.

3. In 2016, the company expects it will lose 300,000 individual memberships, and it expects to see a "mid-single-digit" loss margin in this business.

4. The lingering low interest rates are making an impact on Anthem also. "In 2015, net investment income declined 6.5 percent year over year. For 2016, the company is projecting a 4 percent decline from 2015."

5. Anthem also projects a medical loss ratio of 84.9 percent, plus or minus 30. That's based on high claim rates from ACA plans, and an elevated Medicaid level.

More coding, billing and collections news:
ASIPP members attend legislative session, advocate for MIPS changes: 4 notes
Physicians breathe sigh of relief with "pick-your-pace" MACRA options: 5 things to know
Fewer ACA options may help these states' Republican political candidates' platforms: 4 takeaways

Copyright © 2024 Becker's Healthcare. All Rights Reserved. Privacy Policy. Cookie Policy. Linking and Reprinting Policy.

 

Featured Webinars

Featured Whitepapers

Featured Podcast